APGE · As filed with the SEC
Apogee Therapeutics cash flow statement, by quarter
The statement as Apogee Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS · USD
| USD | Q2 2026 3 months ended Jun 30, 2026 | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024 3 months ended Dec 31, 2024 | Q3 2024 3 months ended Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||
| Net loss | — | (74,111,000) | — | — | — | (55,339,000) | — | — |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||||||||
| Depreciation expense | — | 408,000 | — | — | — | 207,000 | — | — |
| Equity-based compensation expense | — | 17,155,000 | — | — | — | 11,126,000 | — | — |
| Amortization of discounts on marketable securities | — | (1,549,000) | — | — | — | (2,379,000) | — | — |
| Non-cash lease expense | — | 980,000 | — | — | — | 857,000 | — | — |
| Changes in operating assets and liabilities: | ||||||||
| Prepaid expenses and other current assets | — | (2,490,000) | — | — | — | 895,000 | — | — |
| Other non-current assets | — | 155,000 | — | — | — | (6,841,000) | — | — |
| Accounts payable | — | 16,000 | — | — | — | 1,374,000 | — | — |
| Operating lease liability | — | (802,000) | — | — | — | (1,014,000) | — | — |
| Accrued expenses | — | 4,668,000 | — | — | — | 2,637,000 | — | — |
| Net cash used in operating activities | — | (55,570,000) | — | — | — | (48,477,000) | — | — |
| Cash flows from investing activities: | ||||||||
| Purchases of marketable securities | — | (183,244,000) | — | — | — | (98,201,000) | — | — |
| Maturities and sales of marketable securities | — | 147,895,000 | — | — | — | 115,500,000 | — | — |
| Purchases of property and equipment | — | — | — | — | — | (4,317,000) | — | — |
| Net cash (used in) provided by investing activities | — | (35,349,000) | — | — | — | 12,982,000 | — | — |
| Cash flows from financing activities: | ||||||||
| Proceeds from issuance of common stock, net of issuance costs | — | 378,169,000 | — | — | — | 0 | — | — |
| Proceeds from issuance of common stock under the ATM Facility, net of issuance costs | — | 28,934,000 | — | — | — | — | — | — |
| Proceeds from exercise of options | — | 4,064,000 | — | — | — | 622,000 | — | — |
| Net cash provided by financing activities | — | 411,167,000 | — | — | — | 622,000 | — | — |
| Decrease in cash, cash equivalents and restricted cash | — | 320,248,000 | — | — | — | (34,873,000) | — | — |
| Cash, cash equivalents and restricted cash, beginning of period | 451,797,000 | 131,549,000 | 107,914,000 | 124,486,000 | 107,210,000 | 142,083,000 | 119,074,000 | 307,593,000 |
| Cash, cash equivalents and restricted cash, end of period | 105,571,000 | 451,797,000 | 131,549,000 | 107,914,000 | 124,486,000 | 107,210,000 | 142,083,000 | 119,074,000 |
| Supplemental disclosures of non-cash activities: | ||||||||
| Operating lease right-of-use asset obtained in exchange for operating lease liability | — | — | — | — | — | 999,000 | — | — |
| Property and equipment in accounts payable | — | — | — | — | — | 229,000 | — | — |
| Unpaid financing cost in accrued liability | — | 728,000 | — | — | — | 37,000 | — | — |
| Issuance of common stock upon exercise of stock options for which proceeds had not yet been received | — | 256,000 | — | — | — | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.